指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

多黏菌素最佳使用国际共识指南

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Ph
指南 / 共识 · Pharmacotherapy · 2019-01-01
一句话结论多黏菌素B与黏菌素(多黏菌素E)的用药选择、剂量、调整与监测等首次形成国际共识推荐,供成人患者参考。

多黏菌素类抗生素黏菌素(多黏菌素E)和多黏菌素B于20世纪50年代上市,未经过现代药物开发流程,近年作为其他方法无法治疗的革兰阴性菌感染的挽救治疗而重新广泛应用。由于存在多种剂量描述习惯、制剂差异、过时的产品信息以及药敏试验的不确定性,临床对其最佳使用和给药仍存在明显困惑。本指南由多学科国际专家组制定,针对成人患者的多黏菌素药物选择、剂量、剂量调整与监测、联合治疗、鞘内治疗、吸入治疗、毒性及肾功能衰竭预防等给出共识治疗推荐。这是首个关于黏菌素和多黏菌素B治疗的共识推荐,旨在指导最佳临床使用。

要点

  • 多黏菌素B与黏菌素(多黏菌素E)因制剂、剂量描述习惯和药敏试验不确定性,临床使用长期存在困惑。
  • 本指南由国际多学科专家组制定,针对成人患者给出药物选择、剂量、调整与监测等共识推荐。
  • 指南涵盖多黏菌素类联合治疗、鞘内治疗、吸入治疗、毒性及肾功能衰竭预防等临床问题。
  • 这是首个关于黏菌素和多黏菌素B治疗的共识推荐,旨在指导最佳临床使用。
  • 指南获ACCP、IDSA、ISAP、SCCM、SIDP认可,ESCMID认可为共识声明,EUCAST认可总体结论。

适用人群与场景

  • 成人患者,适用于需要多黏菌素类药物(黏菌素或多黏菌素B)治疗的革兰阴性菌感染。

处置流程与药物剂量

  • 专家组针对多黏菌素类药物选择、剂量、剂量调整与监测、联合治疗、鞘内治疗、吸入治疗、毒性及肾功能衰竭预防等给出共识治疗推荐。

研究设计与关键结果

  • 制定机构为国际多学科专家组;指南获美国临床药学院(ACCP)、美国感染病学会(IDSA)、国际抗感染药理学会(ISAP)、美国重症医学会(SCCM)、美国感染病药师学会(SIDP)认可,欧洲临床微生物与感染病学会(ESCMID)认可为共识声明,欧洲抗菌药物敏感性试验委员会(EUCAST)认可总体结论。

证据类型、等级与局限

  • 证据类型:国际共识指南;推荐强度与证据等级原文未报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出具体推荐。

指南或共识出处

  • 多黏菌素最佳使用国际共识指南,获ACCP、ESCMID、IDSA、ISAP、SCCM、SIDP认可。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the 1950s and thus did not undergo contemporary drug development procedures. Their clinical use has recently resurged, assuming an important role as salvage therapy for otherwise untreatable gram-negative infections. Since their reintroduction into the clinic, significant confusion remains due to the existence of several different conventions used to describe doses of the polymyxins, differences in their formulations, outdated product information, and uncertainties about susceptibility testing that has led to lack of clarity on how to optimally utilize and dose colistin and polymyxin B. We report consensus therapeutic guidelines for agent selection and dosing of the polymyxin antibiotics for optimal use in adult patients, as endorsed by the American College of Clinical Pharmacy (ACCP), Infectious Diseases Society of America (IDSA), International Society of Anti-Infective Pharmacology (ISAP), Society for Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) endorses this document as a consensus statement. The overall conclusions in the document are endorsed by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). We established a diverse international expert panel to make therapeutic recommendations regarding the pharmacokinetic and pharmacodynamic properties of the drugs and pharmacokinetic targets, polymyxin agent selection, dosing, dosage adjustment and monitoring of colistin and polymyxin B, use of polymyxin-based combination therapy, intrathecal therapy, inhalation therapy, toxicity, and prevention of renal failure. The treatment guidelines provide the first ever consensus recommendations for colistin and polymyxin B therapy that are intended to guide optimal clinical use.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

参考来源

  1. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019. PMID: 30710469. doi:10.1002/phar.2209

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。